Journal of clinical monitoring and computing · 2024
A novel wearable bioimpedance sensor for continuous monitoring of fluid balance: a study on isotonic hypovolemia in healthy adults.
СтатьяКлиническое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Noddeland Harald, Bremnes Frida, Thorud Anne, Rolid Katrine, Kvaerness Jørn, Jaatun Ellen Andreassen, Aas Sigve Nyvik
Аннотация
PURPOSE: This study aimed to investigate the ability of a novel wearable bioimpedance sensor to monitor changes in fluid balance induced by furosemide. Because iso-osmotic fluid loss is expected to primarily comprise fluid from the extracellular compartment it was hypothesized that isotonic hypovolemia would increase the extracellular resistance (RE).
METHODS: 27 healthy adults (20 women, 7 men; 35 ± 10 year.) were continuously monitored by the bioimpedance sensor following administration of furosemide. Body weight, blood pressure, heart rate, sensation of thirst and selected blood parameters were tested before furosemide administration (t0), one hour (t1) and two hours (t2) after furosemide administration, and one hour after intake of a sports drink containing carbohydrate and electrolytes (t3). Urine elimination was measured throughout the intervention, and the change in extracellular fluid volume was estimated using urine elimination and established equations.
RESULTS: During hypovolemia body weight was reduced by 1.4 ± 0.2 kg (1.7 ± 0.4%). Total urine elimination during fluid loss was 1277 ± 190 mL. RE increased significantly from t0 to t2 (13.6 ± 2.9%). A strong correlation was observed between the estimated change in extracellular fluid volume and the measured change in RE during the isotonic fluid loss.
CONCLUSION: This study demonstrates that the wearable bioimpedance device tested is very sensitive to furosemide-induced changes in fluid volume in healthy volunteers in a controlled environment. Additional research is needed to evaluate the ability of the device to track fluid status in a clinical setting.
TRIAL REGISTRATION: The study was registered at clinicaltrials.gov 29th of October 2021 (NCT05129358).
METHODS: 27 healthy adults (20 women, 7 men; 35 ± 10 year.) were continuously monitored by the bioimpedance sensor following administration of furosemide. Body weight, blood pressure, heart rate, sensation of thirst and selected blood parameters were tested before furosemide administration (t0), one hour (t1) and two hours (t2) after furosemide administration, and one hour after intake of a sports drink containing carbohydrate and electrolytes (t3). Urine elimination was measured throughout the intervention, and the change in extracellular fluid volume was estimated using urine elimination and established equations.
RESULTS: During hypovolemia body weight was reduced by 1.4 ± 0.2 kg (1.7 ± 0.4%). Total urine elimination during fluid loss was 1277 ± 190 mL. RE increased significantly from t0 to t2 (13.6 ± 2.9%). A strong correlation was observed between the estimated change in extracellular fluid volume and the measured change in RE during the isotonic fluid loss.
CONCLUSION: This study demonstrates that the wearable bioimpedance device tested is very sensitive to furosemide-induced changes in fluid volume in healthy volunteers in a controlled environment. Additional research is needed to evaluate the ability of the device to track fluid status in a clinical setting.
TRIAL REGISTRATION: The study was registered at clinicaltrials.gov 29th of October 2021 (NCT05129358).